The gp120 V1V2 region induces antibodies in infected individuals (29), and results from the RV144 clinical vaccine trial indicated that antibody responses against the V1V2 region correlated inversely with the risk of infection (30, 31). The gene discussed is ITIH4; the disease is infection.